focus -WSS

focus

author：knowledge 2025-10-01 15:39:46 - browse：44734

Golden brain and DNA spiral illustration. -- biotech coverage from STAT — Adobe

The dream of being able to pluck a cell therapy off of a freezer shelf and speedily give it to cancer patients is materializing in the cancer world. Now, a new biotech hopes to do the same for patients with neurological conditions.

Kenai Therapeutics closed a $82 million Series A round Thursday co-led by Cure Ventures, The Column Group, and sovereign wealth fund Alaska Permanent Fund Corp. The San Diego-based biotech has big plans for that money — it’s already identified its lead drug candidate for people with Parkinson’s disease, and plans to move into a clinical trial within the next year.

Kenai — pronounced key-nigh — is developing therapies that use induced pluripotent stem cells, or iPSCs. These highly versatile organisms are derived from skin or blood cells and can be transformed into any type of cell. In Parkinson’s, the idea is that these cells would replace damaged neurons.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： United colonoscopy coverage change 'may cost lives,' doctors say

WSS

Affirmative action in medical school literally saved lives

In Memoriam: Notable people who died in 2023

AstraZeneca bets AAV gene therapy will still deliver the goods

Why more medical students aren't specializing in primary care

Novavax promises a turnaround & Lilly roils the obesity market

AstraZeneca challenges Medicare drug negotiation program

Wikipedia

focus

leisure time

What does generative AI mean for health care? We asked experts

Trump demands the U.S. pay no more for drugs than other countries … again

Medicare proposal to cover medical devices draws a mixed reaction

In Memoriam: Notable people who died in 2023

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Peter Hotez and the public health issue of online harassment

Peter Hotez and the public health issue of online harassment

Medical leaders decry Supreme Court decision on affirmative action

Continuity nursing helped my family in our darkest PICU moments

FDA panel gives mixed vote on blood pressure devices

hotspot

Drug repurposing or repositioning? The language matters

Moonlake's readout produced a cash windfall. Risks remain

Feds fine Medicare Advantage plans for overcharging members

AstraZeneca challenges Medicare drug negotiation program

Medicare details structure of new drug price negotiation program

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

entertainment

Wikipedia

hotspot

focus